Papers (2012 – Current)
Click here for a comprehensive list of our publications in PubMed
2020
Park J, Lai MK, Arumugam TV, Jo DG. O-GlcNAcylation as a Therapeutic Target for Alzheimer’s Disease.
___________
2019
Chai YL, Chong JR, Weng J, Howlett D, Halsey A, Lee JH, Attems J, Aarsland D, Francis PT, Chen CP, Lai MK. Lysosomal cathepsin D is upregulated in Alzheimer’s disease neocortex and may be a marker for neurofibrillary degeneration.
___________
2018
Chong JR, Xiang P, Wang W, Hind T, Chew WS, Ong WY, Lai MK, Herr DR. Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications.
Chew WS, Seow WL, Chong JR, Lai MK, Torta F, Wenk MR, Herr DR. Sphingolipidomics analysis of large clinical cohorts. Part 1: Technical notes and practical considerations.
Zhu Y, Hilal S, Chai YL, Ikram MK, Venketasubramanian N, Chen CP, Lai MK. Serum hepatocyte growth factor is associated with small vessel disease in Alzheimer’s dementia.
Chai YL, Xing H, Chong JR, Francis PT, Ballard CG, Chen CP, Lai MK. Mitochondrial translocase of the outer membrane (TOM) alterations may underlie dysfunctional oxidative phosphorylation in Alzheimer’s disease.
___________
2017
Datta A, Chai YL, Tan JM, Lee JH, Francis PT, Chen CP, Sze SK, Lai MK. An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias.
Lee C, Low CY, Wong SY, Lai MK, Tan MG. Selective induction of alternatively spliced FynT isoform by TNF facilitates persistent inflammatory responses in astrocytes.
Zhu Y, Chai YL, Hilal S, Ikram MK, Venketasubramanian N, Wong BS, Chen CP, Lai MK. Serum IL-8 is a marker of white-matter hyperintensities in patients with Alzheimer’s Disease.
Kumar JR, Rajkumar R, Jayakody T, Marwari S, Hong JM, Ma S, Gundlach AL, Lai MK, Dawe GS. Relaxin’ the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.
Chong JR, Chai YL, Lee JH, Howlett D, Attems J, Ballard CG, Aarsland D, Francis PT, Chen CP, Lai MK. Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer’s Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load.
___________
2016
Lee JH, Francis PT, Ballard CG, Aarsland D, Kalaria RN, Wong PT, Chen CP, Lai MK. Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson’s Disease Dementia.
Wong SY, Tan MG, Wong PT, Herr DR, Lai MK. Andrographolide induces Nrf2 and heme oxygenase 1 in astrocytes by activating p38 MAPK and ERK.
Xing H, Lim YA, Chong JR, Lee JH, Aarsland D, Ballard CG, Francis PT, Chen CP, Lai MK. Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias.
Chai YL, Hilal S, Chong JP, Ng YX, Liew OW, Xu X, Ikram MK, Venketasubramanian N, Richards AM, Lai MK, Chen CP. Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia.
Lai MK, Chew WS, Torta F, Rao A, Harris GL, Chun J, Herr DR. Biological effects of naturally occurring sphingolipids, uncommon variants, and their analogs.
Gallart-Palau X, Lee BS, Adav SS, Qian J, Serra A, Park JE, Lai MK, Chen CP, Kalaria RN, Sze SK. Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer’s disease with cerebrovascular disease.
Yang Y, Torta F, Arai K, Wenk MR, Herr DR, Wong PT, Lai MK. Spingosine kinase inhibition ameliorates chronic hypoperfusion-induced white matter lesions.
Wong SY, Tan MG, Banks WA, Wong WS, Wong PT, Lai MK. Andrographolide attenuates LPS-stimulated up-regulation of C-C and C-X-C motif chemokines in rodent cortex and primary astrocytes.
Zhang J, Rane G, Dai X, Shanmugam MK, Arfuso F, Samy RP, Lai MK, Kappei D, Kumar AP, Sethi G. Ageing and the telomere connection: An intimate relationship with inflammation.
Lee C, Low CY, Francis PT, Attems J, Wong PT, Lai MK, Tan MG. An isoform-specific role of fyn tyrosine kinase in Alzheimer’s disease.
Lee JH, Koh SQ, Guadagna S, Francis PT, Esiri MM, Chen CP, Wong PT, Dawe GS, Lai MK. Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer’s disease patients.
___________
2015
Zhou ZD, Xie SP, Sathiyamoorthy S, Saw WT, Sing TY, Ng SH, Chua HP, Tang AM, Shaffra F, Li Z, Wang H, Ho PG, Lai MK, Angeles DC, Lim TM, Tan EK. F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy.
Gallart-Palau X, Serra A, Wong AS, Sandin S, Lai MK, Chen CP, Kon OL, Sze SK. Extracellular vesicles are rapidly purified from human plasma by PRotein Organic Solvent PRecipitation (PROSPR).
Chan SJ, Chai C, Lim TW, Yamamoto M, Lo EH, Lai MK, Wong PT. Cystathionine β-synthase inhibition is a potential therapeutic approach to treatment of ischemic injury.
Hilal S, Chai YL, Ikram MK, Elangovan S, Yeow TB, Xin X, Chong JY, Venketasubramanian N, Richards AM, Chong JP, Lai MK, Chen C. Markers of cardiac dysfunction in cognitive impairment and dementia.
Mohamed NE, Lee JH, Francis PT, Esiri MM, Chen CP, Lai MK. Differential alterations of neocortical GluN receptor subunits in patients with mixed subcortical ischemic vascular dementia and Alzheimer’s disease.
Howlett DR, Whitfield D, Johnson M, Attems J, O’Brien JT, Aarsland D, Lai MK, Lee JH, Chen C, Ballard C, Hortobágyi T, Francis PT. Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias.
___________
2014
Lai MK, Esiri MM, Tan MG. Genome-wide profiling of alternative splicing in Alzheimer’s disease.
Adav SS, Qian J, Ang YL, Kalaria RN, Lai MK, Chen CP, Sze SK. iTRAQ quantitative clinical proteomics revealed role of Na+K+-ATPase and its correlation with deamidation in vascular dementia.
Miura Y, Miyaji K, Chai YL, Chen CL, Lai MK, Yuki N. Autoantibodies to GM1 and GQ1bα are not biological markers of Alzheimer’s disease.
Wong SY, Chan SJ, Wong WS, Wong PT, Lai MK. Andrographolide attenuates interleukin-1β-stimulated upregulation of chemokine CCL5 and glial fibrillary acidic protein in astrocytes.
Ramirez MJ, Lai MK, Tordera RM, Francis PT. Serotonergic therapies for cognitive symptoms in Alzheimer’s disease: Rationale and current status.
Lam SM, Wang Y, Duan X, Wenk MR, Kalaria RN, Chen CP, Lai MK, Shui G. The brain lipidomes of subcortical ischemic vascular dementia and mixed dementia.
Datta A, Qian J, Chong R, Kalaria RN, Francis P, Lai MK, Chen CP, Sze SK. Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia.
Tan MG, Lee C, Lee JH, Francis PT, Williams RJ, Ramírez MJ, Chen CP, Wong PT, Lai MK. Decreased rabphilin 3A immunoreactivity in Alzheimer’s disease is associated with Aß burden.
Mohamed NE, Howlett DR, Ma L, Francis PT, Aarsland D, Ballard CG, McKeith IG, Chen CP, Lai MK. Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias.
__________
2013
Lim YA, Murray LA, Lai MK, Chen C. NeuroAID® (MLC601) and amyloid precursor protein signaling.
__________
2012
Sheng Y, Lee JH, Medhurst AD, Wilcock GK, Esiri M, Wong PT, Chen CP, Lai MK. Preservation of cortical histamine H3 receptors in ischemic vascular and mixed dementias.
__________